SCWorx Corp., headquartered in New York, New York, is a technology firm primarily dedicated to crafting and marketing advanced information technology solutions and related services for the healthcare industry. Its central aim is to enhance operational efficiency and streamline data flow within hospitals and various medical establishments across the United States. The company delivers a broad spectrum of data-focused services, encompassing the repair, standardization, and interoperability of healthcare information for providers, alongside delivering sophisticated big data analytics for the sector. Its diverse offerings include virtualized item master file repair, expansion, and automation; management of electronic medical records (EMR) and charge description masters (CDM); optimization of contract management; automation of request for proposal (RFP) and rebate processes; integration of acquired management systems; big data analytics modeling; data integration and warehousing; and its proprietary ScanWorx solution. Beyond its core healthcare IT endeavors, SCWorx has diversified into other areas. It operates CageTix, an online event ticketing platform specifically targeting regional mixed martial arts events. Additionally, the company is involved in the provision of personal protective equipment (PPE) and rapid COVID-19 test kits. SCWorx distributes its specialized solutions and services to hospitals and health systems through a multi-channel approach, leveraging both its internal sales team and strategic distribution and reseller partnerships.
WORX: S-3/A · shelf registration
SCWorx Corp. filed Amendment No. 1 to its Form S-3 registering the resale of up to 8,253,352 shares of common stock by selling stockholders, comprised of 399,860 issued shares and up to 7,853,492 warrant shares. Against just 1,387,099 shares outstanding, the registration represents a roughly sixfold potential increase in share count, creating a substantial dilution overhang.
The company will receive no proceeds from selling stockholder sales, though it could receive up to approximately $20.1 million if all warrants are exercised for cash. Certain warrants (all but the September Warrants) contain provisions that can lower exercise prices and increase shares issued, amplifying dilution.
The filing also discloses significant distress signals: two reverse splits in 2026 (1-for-15 in April, 1-for-12 in August), a Nasdaq Hearings Panel delisting decision in September 2026 partially reversed on October 2, 2026 subject to conditions, and going-concern-related forward-looking language. Resumption of selling stockholder sales could pressure WORX shares given the tiny current float.